YMAB
Y-mAbs Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ymabs.com
- Employees(FY) 147
- ISIN US9842411095
Performance
-9.87%
1W
-23.38%
1M
-28.79%
3M
+120.11%
6M
+70.09%
YTD
+21.59%
1Y
Profile
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Investment Analysis Report: YMAB
Overview:
YMAB is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $710.6 million. The company's financial data over the past three years provides insights into its valuation, financial health, earnings and revenue growth, profitability, operating margin, operatin...
Technical Analysis of YMAB 2024-05-10
Overview:
In analyzing the technical indicators for YMAB over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming trading days.
Trend An...
Recent News & Updates
- 2024-05-09 11:58
- 2024-05-09 03:04
- 2024-05-08 23:58
- 2024-05-08 21:57
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-07 18:12
- 2024-05-07 17:55
- 2024-05-07 16:05
- 2024-05-07 09:55
- 2024-05-07 04:05
- 2024-04-26 07:05
- 2024-04-25 19:05
- 2024-04-25 16:05
Y-mAbs to Present at 2024 ASCO Annual Meeting(GlobeNewswire)
- 2024-04-25 04:05
Y-mAbs to Present at 2024 ASCO Annual Meeting(Globenewswire)
- 2024-04-18 09:09
- 2024-03-28 09:55
- 2024-03-27 21:55
- 2024-03-20 07:37
- 2024-03-19 19:37
- 2024-03-14 09:05
- 2024-03-13 21:05
- 2024-03-12 09:55
- 2024-03-11 21:55
- 2024-03-05 12:00
- 2024-03-04 23:00
- 2024-03-04 08:45
- 2024-03-04 07:30
- 2024-03-03 18:30
- 2024-03-03 09:40
Y-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectations(Simply Wall St.)
- 2024-03-01 21:42
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-02-29 17:25
Page 1 of 5
previousnext